Table 1 Active and recently posted neoadjuvant immunotherapy trials

NCT03700905^a

III

nivolumab

NCT03765918^a

III

pembrolizumab

NCT02002182

II

ADXS11–001 (ADXS-HPV) vaccine

NCT02296684^ar

II

pembrolizumab

NCT02488759^r

I/II

nivolumab

NCT02609386^a

II

IRX-2 plus cyclophosphamide, then indomethacin, zinc-containing vitamins and omeprazole

NCT02641093^ar

II

pembrolizumab

NCT03003637^r

I/II

ipilimumab and nivolumab

NCT03021993^r

II

nivolumab

NCT03107182^a

II

nab-paclitaxel, carboplatin, nivolumab

NCT03174275^a

II

carboplatin, nab-paclitaxel, durvalumab

NCT03247712^a

I/II

nivolumab

NCT03342911

II

carboplatin, paclitaxel, nivolumab

NCT03708224^a

II

atezolizumab +/− emactuzumab

NCT03721757^a

II

nivolumab

NCT03737968^a

II

durvalumab +/− tremelimumab

NCT03916627^a

II

cemiplimab

NCT03944915

II

carboplatin, paclitaxel, and nivolumab

NCT03129061

I

carboplatin, nab-paclitaxel, durvalumab

NCT03144778^r

I

durvalumab +/− tremelimumab

NCT03635164^a

I/Ib

RT + durvalumab

NCT03843515

I

nivolumab